comparemela.com

Latest Breaking News On - Leyden lab - Page 1 : comparemela.com

Leyden Laboratories B V : Leyden Labs Intranasal PanFlu Antibody Enters the Clinic

Leyden Laboratories B.V., (the "Company" or "Leyden Labs") announced today the dosing of the first Phase 1 healthy volunteer cohort with a nasal spray containing PanFlu candidate CR9114. CR9114 is

Olivia durrElizabeth goodwinJaap goudsmitLeyden labCompany or leyden labsJanssen pharmaceuticals incCompany phaseJanssen pharmaceutical companies of johnsonLeyden labsChief scientificKoenraad wiedhaupChief executive officerJanssen pharmaceuticalsJanssen pharmaceutical companies

Special Note Regarding Forward-Looking Statements Certain statements in this Report contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of. | November 14, 2022

New yorkUnited statesUtah state universityNew jerseyNew brunswickArgentine republicPawel kalinskiRobertp edwardsAlimentosy tecnologiaRintatolimod ampligenRoswell parkHemispherx biopharma europeMonserrato cagliariContract research organizationNational cancer instituteContract manufacturing organization

Special Note Regarding Forward-Looking Statements Certain statements in this Report contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of. | May 13, 2022

New yorkUnited statesUtah state universityNew jerseyNew brunswickArgentine republicPawel kalinskiRintatolimod ampligenRoswell parkAlimentosy tecnologiaRobertp edwardsCasper van eijckHemispherx biopharma europeMonserrato cagliariContract research organizationUs centers for disease

Leyden Laboratories Closes $140M Series B Financing

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Noord hollandDinko valerioSuha jhaveriRonald brusJaap goudsmitEli casdinVali barsanSuzanne jung angellLeyden labSoftbank vision fundJanssen pharmaceuticalsCasdin capitalGoogle venturesBluebird venturesF prime capitalSoftbank investment advisers

Following Janssen flu deal, Leyden Labs gets $140M led by Casdin Capital and GV

Leyden Labs is developing nasal spray medicines to prevent respiratory viral infections. The company’s Series B round of funding follows a licensing deal that gives the biotech rights to a Janssen antibody designed to address the two types of influenza that cause seasonal flu.

United statesNoord hollandJohnson covidCenters for diseaseLeyden labSoftbank vision fundLeyden labsDisease controlMedcity newsBluebird venturesF prime capitalWeight lossMedical devicesHealthcare innovationMedcity newsSan francisco

vimarsana © 2020. All Rights Reserved.